Avenge Bio

Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors. Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies. The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.

Avenge Bio secures FDA designation for mesothelioma therapy

Avenger Bio Insecticide

First Patient Dosed in Immunotherapy Trial for Relapsed Refractory Ovarian Cancer

Reality of Rare Diseases: A Unique Perspective About Rare Diseases

Michael Heffernan on LinkedIn: Avenge Bio Presents Preclinical Data at the American Society of Gene &…

Webinar on Clinical Manufacturing

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

Michael Heffernan on LinkedIn: I am excited to announce the closing of Avenge Bio's $45 million Series A…

BioCentriq Announces Successful Tech Transfer From Avenge Bio for Manufacturing of Drug Product AVB-001 Resulting in Dosing of First Patient in Phase 1/2 Clinical Trial

Douglas Carlson on LinkedIn: Avenge Bio Announces Dosing of First Patient in Phase 1/2 Clinical Trial…

Rice lab's 'drug factory' implants cleared for human trials, Rice News, News and Media Relations

Brendan McLaughlin - Process Development & Manufacturing Scientist - Avenge Bio